HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Directors Find Root Causes But Little Blame For OTC Quality Issues

This article was originally published in The Tan Sheet

Executive Summary

A report by a Johnson & Johnson special committee finds organizational and middle management changes at the firm were the root causes of manufacturing and quality control lapses in the OTC drug business.

You may also be interested in...

In Brief

FDA clarifies pre-emption on OTC labeling

J&J’s Caruso Pitches OTC Comeback To Analysts

Johnson & Johnson will not “shortchange” its commitment to returning its recalled consumer brands to the marketplace, Chief Financial Officer Dominic Caruso says.

J&J Consumer Recaptures Growth, Plans To Restore Most OTCs By Mid-2012

Johnson & Johnson reported July 19 the first period of positive growth for its consumer unit in more than a year.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts